1. Metabolic Disease

Metabolic Disease

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P2799
    Creatine phosphokinase, Rabbit muscle 9001-15-4
    Creatine phosphokinase, Rabbit muscle (CPK) catalyzes the reversible reaction of creatine and ATP to form phosphocreatine and ADP. Creatine phosphokinase is a key enzyme for maintaining a constant ATP/ADP ratio during rapid energy turnover.
    Creatine phosphokinase, Rabbit muscle
  • HY-P3954
    Somatostatin-28 (sheep, human rat mouse) 73032-94-7 99.67%
    Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion.
    Somatostatin-28 (sheep, human rat mouse)
  • HY-108448
    N-Oleoyldopamine 105955-11-1 99.47%
    N-Oleoyldopamine (OLDA) is an orally active TRPV1 activator and 5-LOX inhibitor with blood-brain barrier permeability. N-Oleoyldopamine excites histaminergic neurons in the tuberomammillary nucleus via a dopamine receptor mechanism, a process independent of TRPV1 and cannabinoid receptors. On one hand, N-Oleoyldopamine promotes the release of insulin and glucose-dependent insulinotropic polypeptide through a GPR119-dependent pathway to improve glucose tolerance; on the other hand, N-Oleoyldopamine improves left ventricular function and reduces myocardial infarction size by triggering the release of substance P and calcitonin gene-related peptide. N-Oleoyldopamine is used in studies related to glycemic abnormalities and myocardial ischemia-reperfusion injury.
    N-Oleoyldopamine
  • HY-112415
    Lith-O-Asp 881179-02-8 98.0%
    Lith-O-Asp is a sialytransferase (ST) inhibitor, with IC50s of 12-37 μM.
    Lith-O-Asp
  • HY-113166
    Dodecanoylcarnitine 25518-54-1 ≥99.0%
    Dodecanoylcarnitine ((-)-Lauroylcarnitine) is a medium long-chain acylcarnitine, an intermediate product in key energy metabolic pathways of fatty acid β-oxidation and amino acids catabolism. The abnormal decrease in the Dodecanoylcarnitine levels indicats that mitochondrial fuel metabolism, including fatty acid oxidation is significantly disturbed. Changes in plasma concentrations of Dodecanoylcarnitine are not only associated with type II diabetes, but also with pre-diabetes status. Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease. Dodecanoylcarnitine deomonstrates high sensitivities and specificities in predicting asthma. Combined model of Decanoylcarnitine (HY-113069), Dodecanoylcarnitine, PC (16:0/0:0), and Asp Arg Pro can be used as a potential biomarker for the diagnosis of Yin-deficiency-heat syndrome.
    Dodecanoylcarnitine
  • HY-116152
    Cipepofol 1637741-58-2 99.82%
    Cipepofol (Ciprofol), a novel 2,6-disubstituted phenol derivative, is a positive allosteric modulator and direct agonist of the GABAA receptor. Cipepofol can cause the central nerve inhibition and promote sleep based on the structural modification of Propofol (HY-B0649). Cipepofol can activate the sirtuin1 (Sirt1)/Nrf2 pathway. Cipepofol protects the heart against Isoproterenol (ISO; HY-B0468)-induced myocardial infarction by reducing cardiac oxidative stress, inflammatory response and cardiomyocyte apoptosis.
    Cipepofol
  • HY-132613
    Lumasiran sodium 1834612-06-4 99.21%
    Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
    Lumasiran sodium
  • HY-153660
    Bivamelagon 2641595-54-0 99.50%
    Bivamelagon (MC-4R Agonist 2) is an orally active MC4R agonist with EC50 values of 0.562 nM (Luci assay) and 36.5 nM (cAMP assay), and a Ki of 65 nM. Bivamelagon can be used for the research of diseases such as obesity and diabetes.
    Bivamelagon
  • HY-E70285
    beta-1,4-Galactosyltransferase 1 (Y285L)
    beta-1,4-Galactosyltransferase 1 (Y285L) can enzymatic synthesis of the LacdiNAc motif. beta-1,4-Galactosyltransferase 1 (Y285L) can transfer of GalNAc from UDP-GalNAc.
    beta-1,4-Galactosyltransferase 1 (Y285L)
  • HY-N0182R
    Fisetin (Standard) 528-48-3 98.94%
    Fisetin (Standard) is the analytical standard of Fisetin. This product is intended for research and analytical applications. Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.
    Fisetin (Standard)
  • HY-N1428S
    Citric acid-d4 147664-83-3 99.31%
    Citric acid-d4 is the deuterium labeled Citric acid (HY-N1428). Citric acid is a natural preservative and food tartness enhancer. Citric acid induces apoptosis and cell cycle arrest at G2/M phase and S phase in HaCaT cells. Citric acid cause oxidative damage of the liver by means of the decrease of antioxidative enzyme activities. Citric acid is also an acidulant, emulsifier, sequestrant and buffering agent widely used across many industries.
    Citric acid-d4
  • HY-113378S
    3-Hydroxybutyric acid-d4 sodium 1219804-68-8 99.74%
    3-Hydroxybutyric acid-d4 (sodium) is the deuterium labeled 3-Hydroxybutyric acid. 3-Hydroxybutyric acid (β-Hydroxybutyric acid) is a metabolite that is elevated in type I diabetes. 3-Hydroxybutyric acid can modulate the properties of membrane lipids.
    3-Hydroxybutyric acid-d4 sodium
  • HY-W004049
    3-Hydroxybenzoic acid 99-06-9 99.95%
    3-Hydroxybenzoic acid is an orally active endogenous metabolite. 3-Hydroxybenzoic acid is an agonist for GPR81 and GPR109A. 3-Hydroxybenzoic acid acts as stress response desensitizers. 3-Hydroxybenzoic acid can be used for anti-inflammatory and analgesic study.
    3-Hydroxybenzoic acid
  • HY-W011053
    Neotame 165450-17-9 ≥98.0%
    Neotame is a derivative of Aspartame (HY-B0361) and is a flavor enhancer and low-caloric, non-nutritive, high-intensity artificial sweetener that is 7000-13,000 times sweeter than sugar. Neotame causes intestinal epithelial cell death at high concentrations. Neotame induces Apoptosis of Caco-2 cells.
    Neotame
  • HY-W012241
    Dodecanedioic acid 693-23-2 ≥98.0%
    Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus.
    Dodecanedioic acid
  • HY-W012974
    3-Aminoisobutyric acid 144-90-1 ≥98.0%
    3-Aminoisobutyric acid (β-Aminoisobutyric acid) has anti-inflammatory and antioxidant effects. 3-Aminoisobutyric acid increases the expression of brown adipocyte-specific genes in white adipose tissue and fatty acid β-oxidation in hepatocytes. 3-Aminoisobutyric acid attenuates insulin resistance and inflammation induced by palmitate or a high fat diet via an AMPK-PPARδ-dependent pathway in mice. 3-Aminoisobutyric acid is a catabolic metabolite of thymine and valine in skeletal muscle.
    3-Aminoisobutyric acid
  • HY-W017464
    NAPQI 50700-49-7
    NAPQI is the toxic metabolite of Acetaminophen (HY-66005). NAPQI is also an inhibitor of enzymes in the vitamin K cycle. NAPQI is rapidly detoxified by glutathione (GSH), but in situations of GSH deficiency, excess NAPQI reacts with cysteine residues in proteins, causing cell death and toxicity in the liver.
    NAPQI
  • HY-W053787
    1-Methylhistamine dihydrochloride 6481-48-7 99.89%
    1-Methylhistamine dihydrochloride is a histamine metabolite.
    1-Methylhistamine dihydrochloride
  • HY-W009371C
    D-Ribose 5-phosphate disodium dihydrate 207671-46-3
    D-Ribose 5-phosphate disodium dihydrate is an intermediate of the oxidative branch of the pentose phosphate pathway (PPP) and an end product of the nonoxidative branch of the PPP. D-Ribose 5-phosphate is used in the synthesis of nucleotides and nucleic acids.
    D-Ribose 5-phosphate disodium dihydrate
  • HY-W013636R
    2-Ketoglutaric acid (Standard) 328-50-7 99.52%
    2-Ketoglutaric acid (Standard) (Alpha-Ketoglutaric acid (Standard)) is the analytical standard of 2-Ketoglutaric acid (HY-W013636). This product is intended for research and analytical applications. 2-Ketoglutaric acid (Alpha-Ketoglutaric acid) is an intermediate in the production of ATP or GTP in the Krebs cycle. 2-Ketoglutaric acid also acts as the major carbon skeleton for nitrogen-assimilatory reactions. 2-Ketoglutaric acid is a reversible inhibitor of tyrosinase (IC50=15 mM).
    2-Ketoglutaric acid (Standard)
Cat. No. Product Name / Synonyms Application Reactivity